(0.51%) 5 214.08 points
(0.85%) 39 388 points
(0.27%) 16 346 points
(0.76%) $79.59
(5.44%) $2.31
(1.33%) $2 353.10
(3.52%) $28.57
(0.98%) $994.25
(-0.30%) $0.927
(-0.37%) $10.85
(-0.22%) $0.798
(0.88%) $92.54
Quarter results today
(bmo 2024-05-09)
Expected move: +/- 12.75%
-4.20% $ 1.370
Live Chart Being Loaded With Signals
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U...
Stats | |
---|---|
Dzisiejszy wolumen | 2.04M |
Średni wolumen | 2.54M |
Kapitalizacja rynkowa | 200.54M |
EPS | $0 ( 2024-05-08 ) |
Następna data zysków | ( $-0.0600 ) 2024-08-08 |
Last Dividend | $0.0700 ( 2014-04-28 ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.960 |
ATR14 | $0.00800 (0.58%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-07 | Greco Michele | Buy | 106 000 | Common Stock Option |
2024-05-07 | Barnette K Gary | Buy | 102 000 | Common Stock Option |
2024-05-07 | Fisch Harry | Buy | 102 000 | Common Stock Option |
2024-05-07 | Steiner Mitchell Shuster | Buy | 376 000 | Common Stock Option |
2023-10-02 | Rankowitz Michael L | Buy | 90 000 | Common Stock Option |
INSIDER POWER |
---|
97.10 |
Last 100 transactions |
Buy: 8 197 942 | Sell: 725 000 |
Wolumen Korelacja
Veru Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
AGLE | 0.927 |
MESO | 0.915 |
CNSP | 0.911 |
PRTK | 0.91 |
STER | 0.91 |
AZYO | 0.906 |
MOTNU | 0.897 |
BRY | 0.896 |
TCX | 0.895 |
TTGT | 0.894 |
10 Najbardziej negatywne korelacje | |
---|---|
LWAC | -0.95 |
FANH | -0.894 |
AGFS | -0.892 |
ATHN | -0.892 |
ARIZ | -0.888 |
IMRA | -0.883 |
SDC | -0.883 |
RNDV | -0.878 |
SAGE | -0.872 |
TGLS | -0.867 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Veru Inc Korelacja - Waluta/Towar
Veru Inc Finanse
Annual | 2023 |
Przychody: | $16.30M |
Zysk brutto: | $7.57M (46.43 %) |
EPS: | $-1.100 |
FY | 2023 |
Przychody: | $16.30M |
Zysk brutto: | $7.57M (46.43 %) |
EPS: | $-1.100 |
FY | 2022 |
Przychody: | $39.35M |
Zysk brutto: | $30.59M (77.73 %) |
EPS: | $-1.050 |
FY | 2021 |
Przychody: | $61.26M |
Zysk brutto: | $47.93M (78.24 %) |
EPS: | $0.100 |
Financial Reports:
No articles found.
Veru Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0500 | 2010-01-27 |
Last Dividend | $0.0700 | 2014-04-28 |
Next Dividend | $0 | N/A |
Payout Date | 2014-05-07 | |
Next Payout Date | N/A | |
# dividends | 18 | -- |
Total Paid Out | $1.040 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.68 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2010 | $0.200 | 4.14% |
2011 | $0.200 | 3.50% |
2012 | $0.230 | 4.87% |
2013 | $0.270 | 3.69% |
2014 | $0.140 | 1.67% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Royal | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -2.65 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.498 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.960 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 4.72 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.92 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 3.63 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0454 | -1.500 | 9.24 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -36.63 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.406 | 2.00 | -0.135 | -0.271 | [0 - 30] |
freeCashFlowPerShareTTM | -0.409 | 2.00 | -0.205 | -0.409 | [0 - 20] |
debtEquityRatioTTM | 0.0722 | -1.500 | 9.71 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.341 | 1.000 | 7.64 | 7.64 | [0.2 - 0.8] |
operatingProfitMarginTTM | -2.77 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -18.24 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.188 | 0.800 | -2.08 | -1.665 | [0.5 - 2] |
Total Score | -0.970 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -5.85 | 1.000 | -0.692 | 0 | [1 - 100] |
returnOnEquityTTM | -0.960 | 2.50 | -7.57 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.409 | 2.00 | -0.136 | -0.409 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.406 | 2.00 | -0.135 | -0.271 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 1.229 | 1.500 | 5.14 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -4.41 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -1.353 |
Veru Inc
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej